SPECIALTY GUIDELINE MANAGEMENT

ABECMA (idecabtagene vicleucel)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Abecma is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review: Chart notes, medical record documentation or claims history supporting previous lines of therapy.

III. CRITERIA FOR INITIAL APPROVAL

Multiple Myeloma

Authorization of 3 months may be granted for treatment of relapsed or refractory multiple myeloma in members 18 years of age and older when all of the following are met:

- A. The member has received prior treatment with at least four prior lines of therapy, including at least one drug from each of the following categories:
 - 1. Immunomodulatory agent
 - 2. Proteasome inhibitor
 - 3. Anti-CD 38 monoclonal antibody
- B. The member has not received a previous treatment course of the requested medication or another chimeric antigen receptor (CAR) T-cell therapy directed at any target.
- C. The member has an ECOG performance status of 0 to 2.
- D. The member has adequate and stable kidney, liver, pulmonary and cardiac function.
- E. The member has no history or presence of clinically relevant central nervous system (CNS) pathology
- F. The member does not have clinically significant active infection.
- G. The member does not have active graft versus host disease.
- H. The member does not have an active inflammatory disorder.

IV. REFERENCES

1. Abecma [package insert]. Summit, NJ: Celgene Corporation; March 2021.

Abecma 4642-A SGM P2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.




Reference number(s)

4642-A

- 2. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 Feb 25;384(8):705-716.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Multiple Myeloma. Version 2.2024. Accessed December 14, 2023.
- 4. Patel U, Oluwole OO, Kassim A, et al. Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies. J Clin Oncol. 2023;41(16):e20049.

Abecma 4642-A SGM P2023.docx

© 2023 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written